Quarry LP Purchases New Holdings in Guardant Health, Inc. (NASDAQ:GH)

Quarry LP acquired a new position in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,527 shares of the company’s stock, valued at approximately $44,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Creative Planning purchased a new position in shares of Guardant Health in the second quarter worth $593,000. Algert Global LLC increased its position in Guardant Health by 23.2% in the second quarter. Algert Global LLC now owns 90,220 shares of the company’s stock worth $2,606,000 after buying an additional 17,000 shares in the last quarter. Scientech Research LLC bought a new position in shares of Guardant Health in the second quarter worth about $1,705,000. Mackenzie Financial Corp purchased a new position in shares of Guardant Health during the 2nd quarter valued at about $202,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Guardant Health during the 2nd quarter valued at approximately $71,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Up 1.7 %

Shares of NASDAQ GH opened at $22.16 on Friday. The firm has a market cap of $2.71 billion, a PE ratio of -5.65 and a beta of 1.11. The company has a quick ratio of 6.07, a current ratio of 6.40 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $37.04. The business has a fifty day simple moving average of $26.92 and a two-hundred day simple moving average of $25.33.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The company had revenue of $177.24 million during the quarter, compared to analysts’ expectations of $162.59 million. During the same quarter last year, the firm earned ($0.67) EPS. Guardant Health’s revenue for the quarter was up 29.2% on a year-over-year basis. Analysts expect that Guardant Health, Inc. will post -3.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GH. Bank of America upped their price target on shares of Guardant Health from $28.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, July 18th. Craig Hallum increased their price objective on shares of Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 8th. BTIG Research boosted their price target on shares of Guardant Health from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Citigroup raised their price target on Guardant Health from $40.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Guggenheim raised Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Friday, June 28th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.